Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.41 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.39 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.39 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.39 |
| ▸ | KLKB1 known ✓ | P03952 | 1/20 | 0.39 |
| ▸ | Q9HBH1 | 1/20 | 0.60 | |
| ▸ | SSTR3 | P32745 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3482618 | 1.00 | PDF (0.60) | PDFSSTR3MMP3MMP1MMP9 | |
| Hydrochloric Acid SCHEMBL8853773 | 1.00 | PDF (0.60) | PDFSSTR3MMP3MMP1MMP9 | |
| SCHEMBL27750016 | 0.99 | PDF (0.61) | PDFSSTR3MMP3MMP1MMP9 | |
| SCHEMBL547491 | 0.99 | PDF (0.61) | PDFSSTR3MMP3MMP1MMP9 | |
| SCHEMBL386663 | 0.99 | PDF (0.61) | PDFSSTR3MMP3MMP1MMP9 | |
| SCHEMBL8000347 | 0.93 | PDF (0.67) | PDFSSTR3MMP2SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL27484221 | 0.90 | PDF (0.47) | PDFMMP3MMP1SMN1; SMN2LMNA | |
| SCHEMBL27695847 | 0.89 | PDF (0.48) | PDFMMP3MMP1SMN1; SMN2LMNA | |
| SCHEMBL27695845 | 0.89 | PDF (0.48) | PDFMMP3MMP1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL10702560 | 0.88 | PDF (0.64) | PDFSSTR3MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120041536-A | Method for detecting plasmin activity in ultrahigh-temperature sterilized cow milk | 内蒙古蒙牛乳业（集团）股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-4160025-A | Method of producing a blood-coagulation-promoting preparation from human blood plasma | IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE (AT) | 1979-07-03 | — | — | US | claimed |
| US-20250263683-A1 | MODIFIED UROKINASE-TYPE PLASMINOGEN ACTIVATOR POLYPEPTIDES AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED | 2025-08-21 | — | — | US | disclosed |
| CN-120041536-A | Method for detecting plasmin activity in ultrahigh-temperature sterilized cow milk | 内蒙古蒙牛乳业（集团）股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-3344659-B1 | MOLECULAR CONSTRUCTS FOR PREVENTING THE FORMATION OF BLOOD CLOT AND/OR TREATING THROMBOSIS | IMMUNWORK INC (TW) | 2025-03-26 | — | — | EP | disclosed |
| CN-118922548-A | Antibodies binding to fibrin, fibrinolytic proteins containing the antibodies and pharmaceutical preparations containing the proteins | 株式会社凛研究所 | 2024-11-08 | — | — | CN | disclosed |
| US-11613744-B2 | Modified urokinase-type plasminogen activator polypeptides and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-28 | — | — | US | disclosed |
| US-10967062-B2 | Functionalized nanoparticles and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-04-06 | — | — | US | disclosed |
| US-10383947-B2 | Pharmaceuticals in joint-linker configurations for treating pathological blood clots | Immunwork Inc. (TW) | 2019-08-20 | — | — | US | disclosed |
| US-10357448-B2 | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180243423-A1 | FUNCTIONALIZED NANOPARTICLES AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-08-30 | — | — | US | disclosed |
| US-5985607-A | GENE EXPRESSION CONTROL SEQUENCE | CANGENE CORPORATION (CA) | 1999-11-16 | — | — | US | disclosed |
| US-5886146-A | N-ACYLATED OR SULFONATED TRIPEPTIDES FROM PROLINE, ARGININE AND AMINO ACID WITH CARBOXY OR TETRAZOLE GROUP | CORVAS INTERNATIONAL, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5770600-A | Methionine sulfone and S-substituted cysteine sulfone derivatives as enzyme inhibitors | CORVAS INTERNATIONAL, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5681844-A | ANTITHROMBOTIC AGENTS, ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5646165-A | ANTITHROMBOTIC AGENTS | CORVAS INTERNATIONAL, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1990002338-A1 | RECOMBINANT HYBRID IMMUNOGLOBULIN MOLECULES AND METHOD OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355068-A2 | Recombinant hybrid immunoglobulin molecules and their use | THE GENERAL HOSPITAL CORPORATION (US) | 1990-02-21 | — | — | EP | disclosed |
| US-4257940-A | Valylleucyllysine derivatives, process for producing same and method for measuring activity of enzymes using same | TORII & CO., LTD. (JP) | 1981-03-24 | — | — | US | disclosed |
| US-4160025-A | Method of producing a blood-coagulation-promoting preparation from human blood plasma | IMMUNO AKTIENGESELLSCHAFT FUR CHEMISCH-MEDIZINISCHE PRODUKTE (AT) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263683-A1 | MODIFIED UROKINASE-TYPE PLASMINOGEN ACTIVATOR POLYPEPTIDES AND METHODS OF USE | PLAUR, PLAU, SERPINE1 | MMP1 684/4885GLA 1024/4885OPRK1 4031/4885 |
| US-10383947-B2 | Pharmaceuticals in joint-linker configurations for treating pathological blood clots | F2, PLAT, PFKP | MMP1 836/4885GLA 1222/4885OPRK1 2577/4885 |
| US-10967062-B2 | Functionalized nanoparticles and methods of use thereof | FGB, PLAU, PLAUR | MMP1 240/4885GLA 459/4885OPRK1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.